$522 Million is the total value of Rhenman & Partners Asset Management AB's 108 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 22.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | Sell | Allergan Plc | $15,961,000 | -99.9% | 76,000 | -4.4% | 3.06% | +5.2% |
| LLY | Sell | Eli Lilly & Co | $15,813,000 | -99.9% | 215,000 | -15.7% | 3.03% | -6.8% |
| INCY | Sell | Incyte Corp Ltd | $14,038,000 | -99.9% | 140,000 | -24.3% | 2.69% | -2.9% |
| UNH | Sell | United Health Group Inc | $12,006,000 | -99.9% | 75,017 | -42.3% | 2.30% | -20.4% |
| ALXN | Sell | Alexion Pharmaceuticals Inc | $11,220,000 | -99.9% | 91,702 | -43.3% | 2.15% | -31.6% |
| CVS | Sell | CVS Health Corp | $11,047,000 | -99.9% | 140,000 | -12.5% | 2.12% | -6.3% |
| CELG | Sell | Celgene Corp | $10,765,000 | -99.9% | 93,000 | -50.0% | 2.06% | -33.2% |
| BIIB | Sell | Biogen Inc | $10,209,000 | -99.9% | 36,000 | -36.8% | 1.96% | -30.9% |
| REGN | Sell | Regeneron Pharmaceuticals Inc | $9,728,000 | -99.9% | 26,500 | -10.2% | 1.86% | -1.0% |
| CI | Sell | Cigna Corp | $9,204,000 | -99.9% | 69,000 | -17.9% | 1.76% | +1.4% |
| ZBH | Sell | Zimmer Biomet Hgs Inc | $8,256,000 | -99.9% | 80,000 | -5.9% | 1.58% | -9.8% |
| HCA | Sell | HCA Holdings Inc | $7,750,000 | -99.9% | 104,707 | -4.8% | 1.49% | +12.5% |
| HOLX | Sell | Hologic Inc | $6,419,000 | -99.9% | 160,000 | -11.1% | 1.23% | +10.9% |
| SUPN | Sell | Supernus Pharmaceuticals Inc | $6,313,000 | -99.9% | 250,000 | -7.4% | 1.21% | +14.0% |
| JAZZ | Sell | Jazz Pharmaceuticals Plc | $5,552,000 | -99.9% | 50,920 | -15.1% | 1.06% | -8.1% |
| ZLTQ | Sell | ZELTIQ Aesthetics Inc | $5,440,000 | -99.9% | 125,000 | -21.9% | 1.04% | +4.6% |
| ENDP | Sell | Endo International Plc | $4,944,000 | -99.9% | 300,200 | -16.7% | 0.95% | -17.8% |
| VRTX | Sell | Vertex Pharmaceuticals Inc | $4,790,000 | -99.9% | 65,013 | -18.7% | 0.92% | -17.1% |
| ALKS | Sell | Alkermes Plc | $4,202,000 | -99.9% | 75,599 | -56.9% | 0.81% | -38.6% |
| BMRN | Sell | BioMarin Pharmaceutical Inc | $4,142,000 | -100.0% | 50,000 | -64.3% | 0.79% | -61.4% |
| MRK | Sell | Merck & Co Inc | $4,121,000 | -100.0% | 70,000 | -65.0% | 0.79% | -60.1% |
| KITE | Sell | Kite Pharma Inc | $3,587,000 | -99.9% | 80,000 | -11.1% | 0.69% | -13.8% |
| Sell | NeuroDerm Ltd | $3,165,000 | -99.9% | 142,546 | -1.4% | 0.61% | +43.2% | |
| CHRS | Sell | Coherus BioSciences Inc | $3,135,000 | -99.9% | 111,357 | -15.2% | 0.60% | +7.5% |
| RIGL | Sell | Rigel Pharmaceuticals Inc | $3,051,000 | -99.9% | 1,282,000 | -8.4% | 0.58% | -28.3% |
| DVA | Sell | DaVita Inc | $2,889,000 | -99.9% | 45,000 | -18.2% | 0.55% | -4.0% |
| TSRO | Sell | Tesaro Inc | $2,690,000 | -99.9% | 20,000 | -7.0% | 0.52% | +50.9% |
| KERX | Sell | Keryx Biopharmaceuticals Inc | $2,491,000 | -99.9% | 425,111 | -15.0% | 0.48% | +13.3% |
| RDUS | Sell | Radius Health Inc | $2,092,000 | -99.9% | 55,000 | -26.7% | 0.40% | -37.7% |
| PRGO | Sell | Perrigo Co Plc | $2,081,000 | -99.9% | 25,000 | -28.6% | 0.40% | -22.2% |
| WBA | Sell | Walgreens Boots Alliance Inc | $2,069,000 | -100.0% | 25,000 | -61.5% | 0.40% | -52.3% |
| CMRX | Sell | Chimerix Inc | $1,840,000 | -99.9% | 400,000 | -27.3% | 0.35% | -27.1% |
| HALO | Sell | Halozyme Therapeutics Inc | $1,778,000 | -99.9% | 180,000 | -28.0% | 0.34% | -29.0% |
| PODD | Sell | Insulet Corp | $1,319,000 | -99.9% | 35,000 | -38.6% | 0.25% | -31.8% |
| ACHN | Sell | Achillion Pharmaceuticals Inc | $686,000 | -100.0% | 166,000 | -37.6% | 0.13% | -61.4% |
| CAT | Sell | Caterpillar Inc | $144,000 | -99.9% | 1,548 | -28.9% | 0.03% | -9.7% |
| ANTH | Sell | Anthera Pharmaceuticals Inc | $130,000 | -100.0% | 200,000 | -33.3% | 0.02% | -83.3% |
| VRX | Exit | Valeant Pharmaceuticals Inte | $0 | – | -50,000 | -100.0% | -0.20% | – |
| JNJ | Exit | Johnson & Johnson | $0 | – | -15,000 | -100.0% | -0.28% | – |
| RAD | Exit | Rite Aid Corp | $0 | – | -300,000 | -100.0% | -0.37% | – |
| COO | Exit | Cooper Cos Inc/The | $0 | – | -20,000 | -100.0% | -0.57% | – |
| CEMP | Exit | Cempra Inc | $0 | – | -161,000 | -100.0% | -0.62% | – |
| MCK | Exit | Mckesson Corp | $0 | – | -25,000 | -100.0% | -0.66% | – |
| Exit | Anthem Inc | $0 | – | -67,434 | -100.0% | -1.34% | – | |
| Exit | Medtronic Plc | $0 | – | -169,078 | -100.0% | -2.32% | – | |
| Exit | Gilead Sciences Inc | $0 | – | -207,304 | -100.0% | -2.60% | – | |
| Exit | Pfizer Inc | $0 | – | -555,355 | -100.0% | -2.99% | – | |
| SHPG | Exit | Shire Plcsponsored adr | $0 | – | -409,858 | -100.0% | -4.22% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-01-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.